Center’s RSV Research Featured in New Article from Bloomberg School of Public Health

The Center for American Indian Health has been featured in a new article published online by the Johns Hopkins Bloomberg School of Public Health, titled “A New Shot Prevents Serious Illness from RSV.” The article discusses a new product called Nirsevimab, which has recently been shown in clinical studies to significantly reduce severe illness from respiratory syncytial virus (RSV). The Center for American Indian Health was a part of these clinical trials, working with tribal communities to see if nirsevimab worked in communities where it was needed the most.

Dr. Laura Hammitt, MD, director of Infectious Disease Programs, is quoted within the article:

“It’s important that participation in clinical trials is offered to the populations for which the product is intended,” says Laura Hammitt, MD, director of Infectious Disease Programs at the Center for American Indian Health, who led the nirsevimab clinical trials at Center sites in the Southwest U.S.

“RSV bronchiolitis hospitalizations remain a persistent health disparity for Native American infants,” says Hammitt, an associate professor in International Health. “We’re proving effective products for everybody, not just for Anglo populations.”

Read the full article here.

Read about Center’s RSV study here.